Case Report
Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes
Table 1
Case reports of warfarin-dosing in patients with CYP2C9*3*3 and VKORC1-1639 AA genotypes.
| Age (yrs) | Weight (kg) | Gender | Ethnicity | Indication | Target INR | Drug Interaction(s) | Therapeutic warfarin dose (mg/d) | Reference |
| 69 | 79.8 | Female | Japanese | AFib | 1.5–20 | NR | 0.5 | [8] | 71 | 82 | Male | White | AFib | 2.0–3.0 | Amiodarone | 0.9 | [11] | 58 | 70 | Male | Japanese | AFib | NR | Propafenone | 0.25–0.75 | [12] | 68 | 70 | Female | Chinese | AFib | 2.0–3.0 | NR | 0.63 | [13] | 50 | 88 | Male | Chinese | AFib | 2.0–3.0 | NR | 1.25 | [13] | 74 | 54 | Female | White | AFib | 2.0–3.0 | Amiodarone/ Atorvastatin | 0.5 | Present case |
|
|
AFib: atrial fibrillation; NR: none reported.
|